bucindolol has been researched along with Atrial Fibrillation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, WT; Aleong, R; Anand, IS; Bristow, MR; Camm, AJ; Carroll, IA; Connolly, SJ; Dufton, C; Healey, JS; Khaykin, Y; Krueger, SK; Marshall, D; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Ziegler, PD | 1 |
| Parikh, KS; Piccini, JP | 1 |
| Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB | 1 |
| Abraham, WT; Aleong, R; Anand, IS; Ayala-Paredes, F; Bristow, MR; Carroll, IA; Connolly, SJ; Davis, G; Dufton, C; Emery, LL; Healey, JS; Ilkhanoff, L; Kao, DP; Khaykin, Y; Krueger, SK; Marshall, D; Merkely, B; Miloradović, V; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Wranicz, JK; Ziegler, PD | 1 |
| Metra, M; Shah, P | 1 |
| Abraham, WT; Aleong, RG; Anand, IS; Bristow, MR; Davis, G; Fiuzat, M; Liggett, SB; Murphy, GA; O'Connor, CM; Port, JD; Sauer, WH | 1 |
| Aleong, RG; Bristow, MR; Davis, G; Sauer, WH | 1 |
| Black-Maier, E; Piccini, JP; Steinberg, BA | 1 |
| Brunelli, C; Ferrero, S; Meliota, G; Rosa, GM | 1 |
| Aleong, R; Anand, IS; Bristow, MR; Carson, PE; Davis, G; Fiuzat, M; Gottlieb, SS; Kao, DP; Lindenfeld, J; Miller, AB; Murphy, GA; O'Connor, CM; Plehn, JF; Sauer, W; Silver, MA; White, M | 1 |
3 review(s) available for bucindolol and Atrial Fibrillation
| Article | Year |
|---|---|
Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Genotype; Heart Failure; Humans; Pharmacogenetics; Propanolamines; Receptors, Adrenergic, beta-1; Stroke Volume | 2017 |
Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Heart Failure; Humans; Pharmacogenetics; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, beta-1 | 2015 |
Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.
Topics: Adrenergic beta-Antagonists; Animals; Atrial Fibrillation; Heart Failure; Hospitalization; Humans; Propanolamines; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1 | 2017 |
6 trial(s) available for bucindolol and Atrial Fibrillation
| Article | Year |
|---|---|
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Follow-Up Studies; Genotype; Heart Failure; Humans; Male; Propanolamines; Receptors, Adrenergic, beta-1; Time Factors | 2021 |
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Genetic Testing; Genotype; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Propanolamines; Prospective Studies; Receptors, Adrenergic, beta-1; Stroke Volume; Treatment Outcome | 2018 |
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Genotype; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Mortality; Pharmacogenetics; Pharmacogenomic Variants; Precision Medicine; Propanolamines; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Stroke Volume | 2019 |
Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Female; Heart Failure; Humans; Male; Middle Aged; Polymorphism, Genetic; Propanolamines; Prospective Studies; Receptors, Adrenergic, beta-1; Treatment Outcome | 2013 |
New-onset atrial fibrillation predicts heart failure progression.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Disease Progression; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Propanolamines; Proportional Hazards Models; Risk Factors; Ventricular Dysfunction, Left | 2014 |
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Case-Control Studies; Drug Resistance; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Propanolamines; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Retrospective Studies; Treatment Outcome | 2013 |
1 other study(ies) available for bucindolol and Atrial Fibrillation
| Article | Year |
|---|---|
GENETIC-AF: Digging Deeper Into Genotype-Phenotype and Heart Failure-Atrial Fibrillation Interactions.
Topics: Atrial Fibrillation; Genotype; Heart Failure; Humans; Phenotype; Propanolamines | 2019 |